3H Bio Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Later Stage VC
- Investors
-
9
3H Bio General Information
Description
Operator of a bio-venture company intended to research anti-obesity immunotherapy using Hamseong Peltide. The company offers obesity immunotherapy that prevents and treats obesity by enhancing the natural healing mechanism by activating the immune system in the body, enabling healthcare professionals to treat obesity efficiently.
Contact Information
Website
www.threehbio.comCorporate Office
- 3-9, Seongnam-daero 331 beon-gil
- Bundang-gu, Suite 406, 407
- Seongnam, Gyeonggi 13558
- South Korea
Corporate Office
- 3-9, Seongnam-daero 331 beon-gil
- Bundang-gu, Suite 406, 407
- Seongnam, Gyeonggi 13558
- South Korea
3H Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 01-Jan-2024 | Completed | Pre-Clinical Trials | |||
| 5. Early Stage VC | 01-Jan-2023 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC | 01-Jan-2022 | Completed | Stealth | |||
| 3. Accelerator/Incubator | 28-Feb-2021 | Completed | Stealth | |||
| 2. Seed Round | 31-Jan-2021 | Completed | Stealth | |||
| 1. Seed Round | 01-Dec-2019 | Completed | Stealth |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
3H Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
3H Bio Patents
3H Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3189004-A1 | A peptide used for immunotherapeutics | Pending | 22-Jul-2020 | ||
| US-20230134067-A1 | A peptide used for immunotherapeutics | Inactive | 22-Jul-2020 | ||
| AU-2021311894-A1 | Peptide for immunotherapeutic agent | Active | 22-Jul-2020 | ||
| AU-2021311894-B2 | Peptide for immunotherapeutic agent | Active | 22-Jul-2020 | ||
| AU-2025203276-A1 | Peptide for immunotherapeutic agent | Pending | 22-Jul-2020 | C07K14/775 |
3H Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
3H Bio Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Scale Up Partners | Accelerator/Incubator | Minority | ||
| BNK Venture Capital | Venture Capital | Minority | ||
| Honest Ventures | Venture Capital | Minority | ||
| Kingo Investment Partners | Venture Capital | Minority | ||
| Tech Incubator Program for Startup | Accelerator/Incubator |
3H Bio FAQs
-
When was 3H Bio founded?
3H Bio was founded in 2019.
-
Where is 3H Bio headquartered?
3H Bio is headquartered in Seongnam, South Korea.
-
What is the size of 3H Bio?
3H Bio has 7 total employees.
-
What industry is 3H Bio in?
3H Bio’s primary industry is Biotechnology.
-
Is 3H Bio a private or public company?
3H Bio is a Private company.
-
What is 3H Bio’s current revenue?
The current revenue for 3H Bio is .
-
Who are 3H Bio’s investors?
Scale Up Partners, BNK Venture Capital, Honest Ventures, Kingo Investment Partners, and Tech Incubator Program for Startup are 5 of 9 investors who have invested in 3H Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
